BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31911547)

  • 1. Characterization of Immune Dysfunction and Identification of Prognostic Immune-Related Risk Factors in Acute Myeloid Leukemia.
    Tang L; Wu J; Li CG; Jiang HW; Xu M; Du M; Yin Z; Mei H; Hu Y
    Clin Cancer Res; 2020 Apr; 26(7):1763-1772. PubMed ID: 31911547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased TIGIT expressing NK cells with dysfunctional phenotype in AML patients correlated with poor prognosis.
    Liu G; Zhang Q; Yang J; Li X; Xian L; Li W; Lin T; Cheng J; Lin Q; Xu X; Li Q; Lin Y; Zhou M; Shen E
    Cancer Immunol Immunother; 2022 Feb; 71(2):277-287. PubMed ID: 34129052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification.
    Li C; Chen X; Yu X; Zhu Y; Ma C; Xia R; Ma J; Gu C; Ye L; Wu D
    Int J Clin Exp Pathol; 2014; 7(10):6880-8. PubMed ID: 25400771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer cell (NK) subsets and NK-like T-cell populations in acute myeloid leukemias and myelodysplastic syndromes.
    Aggarwal N; Swerdlow SH; TenEyck SP; Boyiadzis M; Felgar RE
    Cytometry B Clin Cytom; 2016 Jul; 90(4):349-57. PubMed ID: 26648320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of Frequencies, Compositions, and/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL.
    Boeck CL; Amberger DC; Doraneh-Gard F; Sutanto W; Guenther T; Schmohl J; Schuster F; Salih H; Babor F; Borkhardt A; Schmetzer H
    J Immunother; 2017; 40(6):224-248. PubMed ID: 28557814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy.
    Knaus HA; Berglund S; Hackl H; Blackford AL; Zeidner JF; Montiel-Esparza R; Mukhopadhyay R; Vanura K; Blazar BR; Karp JE; Luznik L; Gojo I
    JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia.
    Stringaris K; Sekine T; Khoder A; Alsuliman A; Razzaghi B; Sargeant R; Pavlu J; Brisley G; de Lavallade H; Sarvaria A; Marin D; Mielke S; Apperley JF; Shpall EJ; Barrett AJ; Rezvani K
    Haematologica; 2014 May; 99(5):836-47. PubMed ID: 24488563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia.
    Sandoval-Borrego D; Moreno-Lafont MC; Vazquez-Sanchez EA; Gutierrez-Hoya A; López-Santiago R; Montiel-Cervantes LA; Ramírez-Saldaña M; Vela-Ojeda J
    Arch Med Res; 2016 Jan; 47(1):55-64. PubMed ID: 26876298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural killer cells in acute myeloid leukemia patients: from phenotype to transcriptomic analysis.
    Venton G; Labiad Y; Colle J; Fino A; Afridi S; Torres M; Monteuil S; Loriod B; Fernandez-Nunez N; Farnault L; Suchon P; Mattei JC; Rihet P; Bergon A; Nguyen C; Baier C; Costello R
    Immunol Res; 2016 Dec; 64(5-6):1225-1236. PubMed ID: 27481509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.
    Chretien AS; Fauriat C; Orlanducci F; Rey J; Borg GB; Gautherot E; Granjeaud S; Demerle C; Hamel JF; Cerwenka A; von Strandmann EP; Ifrah N; Lacombe C; Cornillet-Lefebvre P; Delaunay J; Toubert A; Arnoulet C; Vey N; Olive D
    Oncotarget; 2017 Jul; 8(30):49548-49563. PubMed ID: 28548938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Siglec-7 is an indicator of natural killer cell function in acute myeloid leukemia.
    Yang L; Feng Y; Wang S; Jiang S; Tao L; Li J; Wang X
    Int Immunopharmacol; 2021 Oct; 99():107965. PubMed ID: 34273636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scrutinizing the Expression and Blockade of Inhibitory Molecules Expressed on T Cells from Acute Myeloid Leukemia Patients.
    Abdolmaleki M; Mojtabavi N; Zavvar M; Vaezi M; Noorbakhsh F; Nicknam MH
    Iran J Allergy Asthma Immunol; 2018 Jun; 17(3):265-273. PubMed ID: 29908544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the Expression of Surface Receptors on NK Cells and NKG2D on Immunocytes in Peripheral Blood of Patients with Nasopharyngeal Carcinoma.
    Xu Y; Zhou R; Huang C; Zhang M; Li J; Zong J; Qiu S; Lin S; Chen H; Ye Y; Pan J
    Asian Pac J Cancer Prev; 2018 Mar; 19(3):661-665. PubMed ID: 29580037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome.
    Chretien AS; Devillier R; Granjeaud S; Cordier C; Demerle C; Salem N; Wlosik J; Orlanducci F; Gorvel L; Fattori S; Hospital MA; Pakradouni J; Gregori E; Paul M; Rochigneux P; Pagliardini T; Morey M; Fauriat C; Dulphy N; Toubert A; Luche H; Malissen M; Blaise D; Nunès JA; Vey N; Olive D
    Proc Natl Acad Sci U S A; 2021 Jun; 118(22):. PubMed ID: 34050021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD26
    Zhou H; Jia B; Annageldiyev C; Minagawa K; Zhao C; Mineishi S; Ehmann WC; Naik SG; Cioccio J; Wirk B; Songdej N; Rakszawski KL; Nickolich MS; Shen J; Zheng H
    Front Immunol; 2023; 14():1169144. PubMed ID: 37457737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC.
    Mazzaschi G; Facchinetti F; Missale G; Canetti D; Madeddu D; Zecca A; Veneziani M; Gelsomino F; Goldoni M; Buti S; Bordi P; Aversa F; Ardizzoni A; Quaini F; Tiseo M
    Lung Cancer; 2019 Jan; 127():153-163. PubMed ID: 30642544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML.
    Zhao C; Jia B; Wang M; Schell TD; Claxton DF; Ehmann WC; Rybka WB; Mineishi S; Naik S; Songdej N; Sivik JM; Hohl RJ; Zeng H; Zheng H
    Br J Haematol; 2020 Mar; 188(5):674-684. PubMed ID: 31573077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of T Cell Exhaustion by the First Donor Lymphocyte Infusion Is Associated with the Persistently Effective Antileukemic Responses in Patients with Relapsed AML after Allo-HSCT.
    Liu L; Chang YJ; Xu LP; Zhang XH; Wang Y; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1350-1359. PubMed ID: 29649617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the immune cell landscape of patients with NAFLD.
    Diedrich T; Kummer S; Galante A; Drolz A; Schlicker V; Lohse AW; Kluwe J; Eberhard JM; Schulze Zur Wiesch J
    PLoS One; 2020; 15(3):e0230307. PubMed ID: 32168345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A skewed distribution and increased PD-1+Vβ+CD4+/CD8+ T cells in patients with acute myeloid leukemia.
    Huang J; Tan J; Chen Y; Huang S; Xu L; Zhang Y; Lu Y; Yu Z; Chen S; Li Y
    J Leukoc Biol; 2019 Sep; 106(3):725-732. PubMed ID: 31136687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.